Vogenx Starts Phase 2b Trial of Mizagliflozin for Post — Bariatric Hypoglycemia
Vogenx today initiated EMERGE, a Phase 2b trial of mizagliflozin for post-bariatric hypoglycemia, which has no FDA-approved treatments. The randomized, placebo-controlled study will enroll approximately 36 adults at about 10 U.S. sites. Participants will receive mizagliflozin or placebo for 28 days to assess safety and